Thursday, July 12, 2012

New Cancer Drugs Reach US Patients Earlier but at a Price

A report released by Tufts Center for the Study of Drug Development concludes that FDA approved more cancer drugs and faster than European regulators during 2000-2011.

(Pills at Hamburger Bahnhof. By yourjoyismylow ; via Flicker)

  • FDA approved 33% more cancer drugs during 2000-2011 than their counteparts in Europe (EMEA): 40 new drugs in US vs 30 in Europe.
  • FDA approval rate is also faster than Europe
  • But, in US the drugs were about 9% more expensive.

Read more analysis of Tufts data at these sites:


Cost of Cancer Drug Development, 4 Billion. Cost to Patient, 0.1 Million. Benefit, Priceless! Business Model, Unsustainable. July 8, 2012.

No comments:

Post a Comment